MP
RLMD icon

Mangrove Partners’s Relmada Therapeutics RLMD Stock Holding History

Mangrove Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Hold
71,705
– – 0.03% 217
2026
Q1 		$499K Buy
71,705
+44,325
+162% +$210K 0.04% 200
2025
Q4 		$132K Buy
+27,380
New +$91.7K 0.01% 343
2022
Q2 		– Sell
-258,094
Closed -$6.97M – 530
2022
Q1 		$6.97M Buy
258,094
+125,000
+94% +$2.58M 0.38% 50
2021
Q4 		$3M Sell
133,094
-26,074
-16% -$580K 0.18% 184
2021
Q3 		$4.17M Buy
159,168
+112,192
+239% +$3M 0.37% 76
2021
Q2 		$1.5M Buy
+46,976
New +$1.63M 0.15% 208

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mangrove Partners's RLMD Position: Q2 2026 in Review

Mangrove Partners held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 71,705 shares worth $496K. The position accounts for 0.03% of the portfolio, ranked #217.

Mangrove Partners first reported a position in RLMD in Q2 2021 and has held it in 7 quarters since. The position peaked at $6.97M in Q1 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Mangrove Partners held 71,705 shares of Relmada Therapeutics worth $496K as of Q2 2026.
  • Mangrove Partners left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.03% of Mangrove Partners's portfolio in Q2 2026, its #217 holding.
  • Mangrove Partners first reported a position in Relmada Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Mangrove Partners's Relmada Therapeutics position peaked at $6.97M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.